EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc.

EYPT

Rank in Stocks #24959
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the... EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Share Price
$0.3195
Last synced: 2026-11-12
Market Cap
$28.51M
Change (1 day)
-10.40%
Change (1 year)
-97.57%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade EyePoint Pharmaceuticals, Inc. (EYPT)

Category

Healthcare
EPS for EyePoint Pharmaceuticals, Inc. (EYPT)
EPS as of September 2026 TTM: $-3.96
According to EyePoint Pharmaceuticals, Inc.'s latest financial reports, its current EPS (TTM) is $-3.96. At the end of 2025 the company had an EPS of $-3.17, a decrease compared to its 2024 EPS of $-2.32.
EPS history for EyePoint Pharmaceuticals, Inc. from 2002 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-3.96 24.92%
2025 $-3.17 36.64%
2024 $-2.32 27.47%
2023 $-1.82 -33.58%
2022 $-2.74 34.98%
2021 $-2.03 -42.66%
2020 $-3.54 -34.93%
2019 $-5.44 -57.20%
2018 $-12.71 10.52%
2017 $-11.50 119.89%
2016 $-5.23 -23.20%
2015 $-6.81 -409.55%
2014 $2.20 -142.64%
2013 $-5.16 -0.77%
2012 $-5.20 -56.49%
2011 $-11.95 171.59%
2010 $-4.40 -191.67%
2009 $4.80 -442.86%
2008 $-1.40 -98.51%
2007 $-93.93 27.62%
2006 $-73.60 1,184.47%
2005 $-5.73 -75.82%
2004 $-23.70 1,655.56%
2003 $-1.35 145.45%
2002 $-0.55 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 -77.53%
US
$15.66 -495.45%
US
$-7.07 78.54%
US
$-5.29 33.59%
AU
$12.73 -421.52%
BE

Questions about EyePoint Pharmaceuticals, Inc.'s earnings per share (EPS)

What is EyePoint Pharmaceuticals, Inc.'s earnings per share (EPS)?

EyePoint Pharmaceuticals, Inc.'s earnings per share (EPS) over the last twelve months is $-3.96, as of Sep 2026.

What was EyePoint Pharmaceuticals, Inc.'s earnings per share (EPS) in 2025?

In 2025, EyePoint Pharmaceuticals, Inc.'s earnings per share (EPS) was $-3.17, compared with $-2.32 in 2024.

How has EyePoint Pharmaceuticals, Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, EyePoint Pharmaceuticals, Inc.'s earnings per share (EPS) was highest in 2023 ($-1.82) and lowest in 2020 ($-3.54).

How does EyePoint Pharmaceuticals, Inc.'s earnings per share (EPS) compare with similar companies?

EyePoint Pharmaceuticals, Inc.'s earnings per share (EPS) ($-3.96) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.